sponsored
PatientsVille.com Logo

PatientsVille

ASPIRE Medical Research Studies

Up-to-date List of ASPIRE Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest ASPIRE Medical Research Studies

Rank Status Study
1 Unknown  Project Aspire Efficacy Pilot: Achieving Superior Parental Involvement for Rehabilitative Excellence
Condition: Parental Language Behaviors
Interventions: Behavioral: Linguistic Feedback Report;   Behavioral: Multimedia Education Sessions;   Behavioral: EI-As-Usual
Outcome Measures: Parental Behavior Change - Language ENvironment Analysis (LENA): Quantitative Linguistic Change;   Child Behavior Change - LENA: Quantitative;   Center for Epidemiological Studies Depression Screen, short form (CESD-10);   MacArthur Child Development Inventories (CDIs);   Scale of Parental Involvement and Self-Efficacy (SPISE);   Early Intervention Parenting Self-Efficacy Scale (EIPSES);   Aspire Knowledge Questionnaire;   Demographics;   Parent Stress Index (PSI);   Little Ears;   Ages and Stages Questionnaire (ASQ);   Child Behavior Checklist (CBCL);   Rosetti;   Capute Scales;   Theories of Intelligence (TOI);   Parental Behavior Change - LENA and Video: Qualitative Changes
2 Recruiting Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (Aspire)
Condition: Prostate Cancer
Intervention:
Outcome Measures: Tumor Histologic Progression Rate;   Tumor Radiologic Progression Rate;   Anxiety Using Cancer Distress Thermometer Scores;   Urinary Function Using International Prostate Symptom Scores;   Erectile Function Using Sexual Health Inventory for Men Scores
3 Recruiting Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities (Aspire PAD)
Condition: Peripheral Arterial Disease, Antiplatelet Therapy
Interventions: Drug: ASA (75-100 mg) + clopidogrel 75 mg: 12m treatment intervention;   Drug: ASA (75-100 mg) + clopidogrel: 1m (control arm)
Outcome Measures: 12-month Primary Endpoint (subject-based):;   Secondary Endpoints through 12 months:
4 Recruiting Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure
Condition: HIV Infection
Interventions: Drug: dolutegravir;   Drug: lamivudine;   Drug: Continue current antiretroviral regimen
Outcome Measures: Virologic failure rate;   CD4 count;   Rates of HIV-1 viremia;   Clinical and laboratory toxicities;   HIV-1 detection by single-copy assay;   Drug resistance associated mutations;   Adherence
5 Recruiting Efficacy of Vakum Technology in Patients With Chronic Hypersecretion
Conditions: Chronic Bronchitis/Bronchiectasis;   Chronic Obstructive Pulmonary Disease
Interventions: Device: VAKÜM system;   Other: conventional manual ELTGOL technique
Outcome Measures: Change in perceived dyspnea;   Change in peak expiratory air flows;   Change in arterial blood gases exchanges;   Change in spirometric lung volumes;   Change in respiratory muscle strength;   Change in sputum volume and characteristics;   Change in quality of life
6 Not yet recruiting Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
Condition: Peripheral Arterial Disease
Interventions: Procedure: Endovascular revascularization;   Drug: 1 month daily 75 mg plavix;   Drug: 12 months daily 75 mg plavix;   Drug: 12 months daily 75-100 mg aspirin;   Drug: 1 month daily 75-100 mg aspirin
Outcome Measures: Target vessel occlusion;   Surgical revascularization;   Endovascular revascularization;   Major amputation of the target limb;   Ischemic Stroke;   Myocardial infarction;   Death;   Bleeding
7 Not yet recruiting R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: R-CHOP;   Radiation: Radiotherapy
Outcome Measures: To compare 3-year event-free survival;   To evaluate and compare OS between the two arms;   To evaluate and compare the ORR and CR rate;   To evaluate and compare disease-free survival (DFS);   To evaluate treatment-failure pattern;   Number of Participants with Adverse Events in each arm;   To assess patient-reported outcomes (PROs) in both arms;   A role of interim PET after 3 cycles of R-CHOP chemotherapy: correlation with PFS and OS
8 Recruiting An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
Condition: Muscle Spasticity
Intervention: Drug: onabotulinumtoxinA
Outcome Measures: Percentage of Patients Reporting Satisfaction with Treatment;   Percentage of Health Care Providers Reporting Satisfaction with Treatment;   Physical Functioning on a 5-Point Scale;   Severity of Pain on an 11-Point Scale;   Disability Assessment on a 4-Point Scale
9 Recruiting Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT
Condition: ADV Infection Post Allo-HSCT
Intervention: Biological: Cytovir-ADV
Outcome Measures: Number of subjects with new onset GVHD;   number of subjects developing NCI Grade 3-4 adverse events;   Number of reported Serious Adverse Events (SAEs), Suspected Unexpected Serious Adverse Reactions (SUSARs) and Suspected Expected Serious Adverse Reactions (SESARs);   Number of detectable HAdV-specific T-cells in vivo at each time point;   Requirement for second infusion of HAdV-specific T-cells;   Number of treatment days with antiviral drugs;   Number of treatment days with other anti-infective drugs;   Number of in-hospital days during 6 month post-infusion period
10 Recruiting Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease
Condition: Angina, Stable
Intervention: Genetic: Alferminogene tadenovec
Outcome Measures: Change in reversible perfusion defect size (RPDS) as measured by adenosine triphosphate (ATP) single-photon emission computed tomography with technetium-99m sestamibi (SPECT);   Change in angina frequency and nitroglycerin use;   Change in quality of life using the Seattle Angina Questionnaire;   Change in patient functional class using CCS anginal classification;   Safety of Ad5FGF-4 as assessed by adverse events and clinical laboratory testing;   Long-term safety of Ad5FGF-4 as assessed by serious adverse events
11 Recruiting Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU
Conditions: Pneumonia;   Pneumonia, Ventilator-Associated;   Nosocomial Pneumonia
Intervention: Other: Various observed exposure(s) of interest
Outcome Measures: Incidence of S. aureus ICU pneumonia;   Incidence of P. aeruginosa ICU pneumonia;   Prevalence of S. aureus / P. aeruginosa ETA colonization;   Incidence of all cause ICU pneumonia;   Incidence of S. aureus ICU pneumonia stratified by MRSA vs. MSSA;   Incidence of P. aeruginosa ICU pneumonia stratified by MDR-PA vs. S-PA;   Incidence of ICU bacteremia per etiologic agent (in case of S. aureus and/or P. aeruginosa and for all clinically relevant other pathogens);   All-cause mortality;   Time to S. aureus ICU pneumonia;   Time to P. aeruginosa ICU pneumonia;   Time to all cause ICU pneumonia;   Time to all cause ICU bacteremia;   Time to death of any cause
12 Recruiting A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostrate Cancer and Men With Metastatic Prostate Cancer
Conditions: Prostate Cancer;   Metastatic Prostate Cancer;   Castration-resistant Prostate Cancer
Intervention:
Outcome Measures: Patterns of disease management;   Clinical outcomes;   Factors influencing physician treatment decisions;   Documentation of healthcare resource utilization used to manage treatment-related complications
13 Recruiting Psoriasis Microbiome and Phototherapy
Condition: Psoriasis
Intervention: Device: NB-UVB Phototherapy
Outcome Measures: Cutaneous microbiota;   Number of patients with adverse events.
14 Recruiting EMST and TMS for Treatment of Dysphagia in Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Device: Expiratory muscle strength training (EMST);   Other: Transcranial magnetic stimulation (TMS)
Outcome Measures: Dysphagia severity as measured by FEES;   Cortical reorganization of swallowing process as detected by MEG;   Changes in quality of life as measured by the SwalQol questionnaire
15 Recruiting Diagnostic Study of Biomarkers in BAL of ICU Patients With Lung Infiltrates
Conditions: INvasive Aspergillosis;   Mechanical Ventilation;   Lung Infiltrates;   Diagnostics;   Biomarker
Intervention:
Outcome Measure: Diagnostic accuracy of combined biomarker testing in BAL fluid in relation to diagnostic certainty
16 Recruiting PRP ULCERAS: Clinical Trial Phase III
Condition: Ulcer
Interventions: Drug: Platelet-Rich Plasma;   Other: Usual treatment
Outcome Measures: ULCER SIZE CHANGE;   QUALITY OF LIFE (INDEX CIVIQ);   Change of the percentage OF PATIENTS WITH A ONLY ONE TREATMENT FOR WEEK
17 Not yet recruiting Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment
Condition: Autism Spectrum Disorders
Intervention: Drug: Memantine-XR
Outcome Measures: cortical metrics (a mathematical plot of tactile responsivity in 3 dimensions);   Clinical Global Impressions - Improvement Score.;   PDD-BI SV change 0-8;   ABC-SW subscale score 0-8
18 Recruiting Brain Imaging of Intranasal Oxytocin Treatment in Autism
Condition: Autism Spectrum Disorders
Intervention: Drug: Oxytocin
Outcome Measures: Aim 1a. fMRI Activation Analysis/Connectivity;   Aim 1b. Proportion of Time Attending to Social Stimuli (Eye Tracking);   Plasma Oxytocin (OT) levels in aim 1b. and 2b.;   Salivary Oxytocin (OT) levels for all aims.;   SRS-Social Responsiveness Scale;   Pervasive Developmental Disorders Behavior Inventory-Screening Version (PDDBI-SV);   ABC-lethargy/social withdrawal subscale
19 Recruiting Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging
Condition: Coronary Artery Disease
Intervention: Drug: Regadenoson
Outcome Measures: Strain (ΔR) and/or displacement (Δθ) of normal and abnormal segments;   Strain (ΔR) and/or displacement (Δθ) between segment classifications (normal, reversible, and non-reversible perfusion defects);   Strain (ΔR) and/or displacement (Δθ) score correlation with flow reserve as measured by PET and/or transmural extent of infarction (TEI) indicated by Late Gadolinium Enhancement (LGE);   Adverse events

These studies may lead to new treatments and are adding insight into ASPIRE etiology and treatment.

A major focus of ASPIRE research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss ASPIRE